Myotonic Dystrophy: EPIC Functions at The Ottawa Hospital

In 2019, the Ottawa Hospital (TOH) introduced a new Electronic Health Record system called EPIC, to move documentation such as orders for blood work, prescriptions, notes and letters from paper-based to online digital formats. This involved a major investment in education and training of hospital staff.

 

A recent initiative highlights how EPIC functions can be tailored to improve the safety of patients with a rare muscle condition called myotonic dystrophy (DM). DM is a genetic condition that leads to muscle weakness and wasting, and to additional health issues such as cardiac arrhythmia, cataracts of the eyes, diabetes, constipation, and disrupted sleep. DM patients also respond with severe side effects to a range of medications and anaesthetics.

 

At the Neuromuscular Centre at TOH there are more than 50 patients with DM under the care of neuromuscular specialists, who aware of the specific risks and health issues associated with DM. However, DM patients frequently need to seek medical attention at other TOH departments, whose staff may not be aware of the DM diagnosis or the specific risks associated with prescriptions.

 

Inspired by a DM family from Ottawa, the TOH medical information team has designed a new EPIC functionality, so-called Best Practice Advisories (BPA), to keep DM patients safe throughout the hospital. Firstly, a side panel alert informs doctors and nurses accessing the patient’s records about the DM diagnosis and provides guidance through a specific “standards of care” document that has been devised by international experts together with the Myotonic Dystrophy Foundation. Secondly, a specific warning will be displayed if the doctor attempts to order a medication that is considered potentially unsafe for DM; to proceed with the order, they are required to acknowledge the warning and explain their reasons.

 

The new BPAs went live in June 2021. If successful, they may be adopted by other hospitals and organisations in Canada to keep DM patients safe.

 

The Neuromuscular Disease Network for Canada (NMD4C) is a network of clinicians, scientists, patients and patient advocacy groups, committed to improving the care, research, and treatment of neuromuscular diseases for all Canadians. The network is encouraged to see projects such as this that engage multiple stakeholders, identifying and addressing issues from different perspectives and fostering collaborations that deliver impactful outcomes.

 

For further information please contact:

James Davis, NMD4C Communications Coordinator

EPIC_DM

Read next...

Journal of neuromuscular diseases

Journal of Neuromuscular Diseases Celebrates 10-Year Anniversary with Commemorative Editorial

The January 2024 edition of the Journal of Neuromuscular Diseases (JND) marked the journal’s 10-year anniversary!

Canadian Neuromuscular Community of Practice

NMD4C and MDC Announce Plans for Neuromuscular Community of Practice

We are thrilled to announce a new neuromuscular Community of Practice (CoP) initiative for neuromuscular healthcare providers! Our CoP will address the need for a centralized hub for neuromuscular HCPs, fostering collaboration, knowledge exchange, and skill enhancement to elevate NMD research and care across Canada. 

NMD4C investigators' research named to Quebec Science Magazine's top 10 discoveries of 2023

NMD4C Investigators’ Research Named to Quebec Science Magazine’s Top 10 Discoveries of 2023

The 31st edition of the Quebec Science magazine’s Top 10 Discoveries of the Year has recognized a publication from NMD4C investigators in their 2023 list of top scientific discoveries from Québec-based researchers. 

Defeat Duchenne grant $17 million over 29-years to fund promising Duchenne research.

Defeat Duchenne Canada Announce 2023-2024 Research Grants

Defeat Duchenne Canada, announce that it will grant $880,320 toward five promising research projects this year.

NMD4C welcomes two new staff members - Marine Christin, PhD and Maria Masnata, PhD

NMD4C Welcomes Two New Staff Members

The NMD4C recently welcomed two new members to the network coordination team! Marine Christin, PhD joins us as the new Pre-Clinical Science Coordinator, and Maria Masnata, PhD joins as the Clinical Trials & Community Practice Manager. 

Congratulations to the 2024 neuromuscular clinical and post-doctoral fellowship recipients. Photos of the fellows with information about their research insitutions.

2024 Recipients of NMD4C and MDC Neuromuscular Fellowship Funding Competition

The Neuromuscular Disease Network for Canada (NMD4C) together with Muscular Dystrophy Canada (MDC) are thrilled to announce the recipients of the National Clinical and Post-doctoral Fellowships funding competition.